Stem cell transplantation in autoimmune diseases: An update

References

• Slavin S. Treatment of life threatening autoimmune diseases with myeloablative doses of immunosuppressive agents and autologous bone marrow transplantation – rationale and experimental background. Bone Marrow Transplant 1993; 12: 85–8
   PubMed Web of Science ®Google Scholar
• Marmont A. M., van Bekkum D. W. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transplant 1995; 6: 497–8
   Google Scholar
• Snowden J. A., Brooks P. M., Biggs J. C. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997; 99: 9–22
   PubMed Web of Science ®Google Scholar
• Tyndall A., Gratwohl A. Blood and marrow stem cell transplants in autoimmune diseases: a consensus report written on the behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 643–5
   PubMed Web of Science ®Google Scholar
• Jantunen E., Myllykangas‐Luosujärvi R. Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives. Bone Marrow Transplant 2000; 25: 351–6
   Google Scholar
• Bingham S. J., Snowden J. A., Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann Med 2000; 32: 615–21
   Web of Science ®Google Scholar
• Burt R. K., Slavin S., Burns W. H., Marmont A. M. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 2002; 99: 768–84
   PubMed Web of Science ®Google Scholar
• Popat U., Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004; 126: 637–49
   PubMed Web of Science ®Google Scholar
• van Bekkum D. W. Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32(Suppl. 1): S37–9
   Google Scholar
• van Bekkum D. W. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201–22
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Slavin S., Ben‐Nun A., Ovadia H., Vourka‐Karussis U., Lehmann D., et al. Chronic‐relapsing experimental autoimmune encephalomyelitis (CR‐EAE): treatment and induction of tolerance with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 1992; 9: 201–10
   Google Scholar
• Hinterberger W., Hinterberger‐Fischer M., Marmont A. Clinically demonstrable anti‐autoimmunity mediated by allogeneic immune cells favourably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002; 30: 753–9
   PubMed Web of Science ®Google Scholar
• Fassas A., Anagnostopoulos A., Kazis A., Kapinas K., Sakellari I., Kimiskidis V., et al. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy. J Clin Immunol 2000; 20: 24–30
   PubMed Web of Science ®Google Scholar
• Kozak T., Havrdova E., Pit'ha J., Gregora E., Pytlik R., Maaloufova J., et al. High‐dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525–31
   PubMedGoogle Scholar
• Carreras E., Saiz A., Marin P., Martinez C., Rovira M., Villamor N., et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year follow‐up in 15 patients. Haematologica 2003; 88: 306–14
   PubMed Web of Science ®Google Scholar
• Burt R. K., Cohen B. A., Russell E., Spero K., Joshi A., Oyama Y., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of total body irradiation‐based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373–8
   PubMed Web of Science ®Google Scholar
• Nash R. A., Bowen J. D., McSweeney P. A., Pavletic S. Z., Maravilla K. R., Park M. S., et al. High‐dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364–72
   PubMed Web of Science ®Google Scholar
• Openshaw H., Stuwe O., Antel J. P., Nash R., Lund B. T., Weiner L. P., et al. Multiple sclerosis flares associated with recombinant granulocyte colony‐stimulating factor. Neurology 2000; 54: 2147–50
   PubMed Web of Science ®Google Scholar
• Fassas A., Passweg J. R., Anagnostopoulos A., Kazis A., Kozak T., Havrdova E., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249: 1088–97
   PubMed Web of Science ®Google Scholar
• Mancardi G. L., Saccardi R., Filippi M., Gualandi F., Murialdo A., Inglese M., et al. Autologous hematopoietic stem cell transplantation suppresses Gd‐enchanced MRI activity in MS. Neurology 2001; 57: 62–8
   PubMed Web of Science ®Google Scholar
• Inglese M., Mancardi G. L., Pagani E., Rocca M. A., Murialdo A., Saccardi R., et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatr 2004; 75: 643–4
   PubMed Web of Science ®Google Scholar
• Bryan C., Knight C., Black C. M., Silman A. J. Prediction of five‐year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660–5
   PubMed Web of Science ®Google Scholar
• Binks M., Passweg J. R., Furst D., McSweeney P., Sullivan K., Besenthal C., et al. A phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact of skin disease. Ann Rheum Dis 2001; 60: 577–84
   PubMed Web of Science ®Google Scholar
• McSweeney P. A., Nash R. A., Sullivan K. M., Storek J., Crofford L. J., Dansey M. D., et al. High‐dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602–10
   PubMed Web of Science ®Google Scholar
• Farge D., Passweg J., van Laar J. M., Marjanovic Z., Besenthal C., Finke J., et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis 2004; 63: 974–81
   PubMed Web of Science ®Google Scholar
• Farge D., Marolleau J. P., Zohar S., Marjanovic Z., Cabane J., Mounier N., et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I‐II study. Br J Haematol 2002; 119: 726–39
   PubMed Web of Science ®Google Scholar
• Jäntti J. K., Kaarela K., Belt E. A., Kautiainen H. J. Incidence of severe outcome in rheumatoid arthritis in 20 years. J Rheumatol 2002; 29: 688–92
   PubMedGoogle Scholar
• Burt R. K., Georganas C., Schroeder J., Traynor A., Stefka J., Schuening F., et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum 1999; 42: 2281–5
   PubMed Web of Science ®Google Scholar
• Snowden J. A., Biggs J. C., Milliken S. T., Fuller A., Brooks P. M. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42: 2286–92
   PubMed Web of Science ®Google Scholar
• Bingham S. J., Snowden J., McGonagle D., Richards S., Isaacs J., Morgan G., et al. Autologous stem cell transplantation for rheumatoid arthritis – interim report of 6 patients. J Rheumatol 2001; 64(Suppl.): 21–4
   Google Scholar
• Verburg R. J., Kruize A. A., van den Hoogen F. H., Fibbe W. E., Petersen E. J., Preijers F., et al. High‐dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001; 44: 754–60
   PubMed Web of Science ®Google Scholar
• Moore J., Brooks P., Milliken S., Biggs J., Ma D., Handel M., et al. A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301–09
   PubMed Web of Science ®Google Scholar
• Snowden J. A., Passweg J., Moore J. J., Milliken S., Cannell P., van Laar J., et al. Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482–8
   PubMed Web of Science ®Google Scholar
• Traynor A. E., Schroeder J., Rosa R. M., Cheng D., Stefka J., Mujais S., et al. Treatment of severe systemic lupus erythematosus with high‐dose chemotherapy and haemopoietic stem‐cell transplantation: a phase I study. Lancet 2000; 356: 701–7
   PubMed Web of Science ®Google Scholar
• Traynor A. E., Barr W. G., Rosa R. M., Rodriquez J., Oyama Y., Baker S., et al. Hematopoetic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002; 46: 236–8
   Google Scholar
• Jayne D., Passweg J., Marmont A., Farge D., Zhao X., Arnold R., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 168–76
   PubMed Web of Science ®Google Scholar
• Wulffraat N., van Royen A., Bierings M., Vossen J., Kuis W. Autologous haemopoietic stem‐cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550–3
   PubMed Web of Science ®Google Scholar
• ten Cate R., Brinkman D. M., van Rossum M. A., Lankester A. C., Bredius R. G., Egeler M. R., et al. Macrophage activation syndrome after autologous stem cell transplantation for systemic juvenile idiopathic arthritis. Eur J Pediatr 2002; 161: 686–8
   PubMedGoogle Scholar
• Wulffraat N. M., Brinkman D., Ferster A., Opperman J., ten Cate R., Wedderburn L., et al. Long‐term follow‐up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003; 32((Suppl. 1))S61–4
   Google Scholar
• Locatelli F., Perotti C., Torretta L., Maccario R., Montagna D., Ravelli A., et al. Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis. Haematologica 1999; 84: 839–43
   PubMed Web of Science ®Google Scholar
• Rossi G., Moretta A., Locatelli F. Autologous haematopoietic stem cell transplantation for severe/refractory intestinal Bechet disease. Blood 2004; 103: 748–50
   PubMed Web of Science ®Google Scholar
• Huhn R. D., Fogarty P. F., Nakamura R., Read E. J., Leitman S. F., Rick M. E., et al. High‐dose cyclophosphamide with autologous lymphocyte‐depleted peripheral blood stem cell (PBSC) support for treatment of refractory autoimmune thrombocytopenia. Blood 2003; 101: 71–7
   PubMed Web of Science ®Google Scholar
• Passweg J., Rabusin M., Musso M., Beguin Y., Cesaro S., Ehninger G., et al. Haematopoietic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol 2004; 125: 749–55
   PubMed Web of Science ®Google Scholar
• Kashyap A., Forman S. Autologous bone marrow transplantation for non‐Hodgkin's lymphoma results in long‐term remission of coincidental Crohn's disease. Br J Haematol 1998; 103: 651–2
   PubMed Web of Science ®Google Scholar
• Söderholm J. D., Malm C., Juliusson G., Sjödahl R. Long‐term endoscopic remission of Crohns's disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand J Gastroenterol 2002; 37: 613–6
   PubMed Web of Science ®Google Scholar
• Ditschkowski M., Einsele H., Schwerdtfeger R., Bunjes D., Trenschel R., Beelen D. W., et al. Improvement of inflammatory bowel disease after allogeneic stem‐cell transplantation. Transplantation 2003; 75: 1745–7
   PubMed Web of Science ®Google Scholar
• Burt R. K., Traynor A., Oyama Y., Craig R. High‐dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn's disease. Blood 2003; 101: 2064–6
   PubMed Web of Science ®Google Scholar
• Kreisel W., Pothoff K., Bertz H., Schmitt‐Graeff A., Ruf G., Rasenack J., et al. Complete remission of Crohn's disease after high‐dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 2003; 32: 337–40
   PubMed Web of Science ®Google Scholar
• Hawkey C. J. Stem cell transplantation for Crohn's disease. Best Pract Res Clin Haematol 2004; 17: 317–25
   Google Scholar
• Oyama Y., Traynor A. E., Barr W., Burt R. K. Allogeneic stem cell transplantation for autoimmune diseases: non‐myeloablative conditioning regimens. Bone Marrow Transplant 2003; 32((Suppl. 1))S81–3
   Google Scholar
• Slavin S., Nagler A., Varadi G., Or R. Graft vs autoimmune lymphocytes (GVA) following allogeneic bone marrow transplantation in a patient with chronic myelogenous leukaemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853–7
   PubMed Web of Science ®Google Scholar
• Gratwohl A; EBMT JACIE Accreditation Office. Overview of transplant activity in Europe., Hematol J. 5. S29–33
   Google Scholar
• Burt R. K., Fassas A., Snowden J., van Laar J., Kozak T., Wulffraat N., et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001; 28: 1–12
   PubMed Web of Science ®Google Scholar
• Crippa F., Holmberg L., Carter R. A., Hooper H., Marr K. A., Bensinger W., et al. Infectious complications after autologous CD34‐selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 281–9
   PubMedGoogle Scholar
• Altes A., Sierra J., Esteve J., Martin‐Henao G., Marin P., Sureda A., et al. CD34+ ‐enriched‐CD19+ ‐depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 2002; 30: 824–30
   PubMed Web of Science ®Google Scholar
• Burt R. K., Kallunian K., Patel D., Thomas J., Yeager A., Traynor A., et al. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total body irradiation in systemic sclerosis. Bone Marrow Transplant 2004; 34: 745–51
   PubMedGoogle Scholar